Shanghai Haoyuan Chemexpress Co. Ltd. A (SHG:688131) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Haoyuan Chemexpress Co. Ltd. A (688131)
Shanghai Haoyuan Chemexpress Co. Ltd. A (SHG:688131) has a market capitalization of $3.12 Billion (CN¥21.31 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #4834 globally and #808 in its home market, demonstrating a 11.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Haoyuan Chemexpress Co. Ltd. A's stock price CN¥100.48 by its total outstanding shares 212103972 (212.10 Million). Also see 688131 total assets for a full breakdown of the balance sheet.
Shanghai Haoyuan Chemexpress Co. Ltd. A Market Cap History: 2021 to 2026
Shanghai Haoyuan Chemexpress Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $2.78 Billion to $3.12 Billion (-2.14% CAGR). Also see 688131 cash generation efficiency for how efficiently the company converts equity into cash flow.
Shanghai Haoyuan Chemexpress Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Haoyuan Chemexpress Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Shanghai Haoyuan Chemexpress Co. Ltd. A stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.78x
Shanghai Haoyuan Chemexpress Co. Ltd. A's market cap is 0.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.03x
Shanghai Haoyuan Chemexpress Co. Ltd. A's market cap is 9.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.78 Billion | $969.23 Million | $190.98 Million | 2.86x | 14.53x |
| 2022 | $1.70 Billion | $1.36 Billion | $193.64 Million | 1.25x | 8.77x |
| 2023 | $1.15 Billion | $1.88 Billion | $127.45 Million | 0.61x | 9.00x |
| 2024 | $1.11 Billion | $2.27 Billion | $201.59 Million | 0.49x | 5.50x |
| 2025 | $2.24 Billion | $2.87 Billion | $247.77 Million | 0.78x | 9.03x |
Competitor Companies of 688131 by Market Capitalization
Companies near Shanghai Haoyuan Chemexpress Co. Ltd. A in the global market cap rankings as of September 24, 2026. Review 688131 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shanghai Haoyuan Chemexpress Co. Ltd. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Shanghai Haoyuan Chemexpress Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Shanghai Haoyuan Chemexpress Co. Ltd. A's market cap moved from $2.78 Billion to $ 3.12 Billion, with a yearly change of -2.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.12 Billion | +39.40% |
| 2025 | CN¥2.24 Billion | +101.90% |
| 2024 | CN¥1.11 Billion | -3.39% |
| 2023 | CN¥1.15 Billion | -32.48% |
| 2022 | CN¥1.70 Billion | -38.80% |
| 2021 | CN¥2.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Shanghai Haoyuan Chemexpress Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.12 Billion USD |
| MoneyControl | $3.12 Billion USD |
| MarketWatch | $3.12 Billion USD |
| marketcap.company | $3.12 Billion USD |
| Reuters | $3.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.